Aadi Biosciences(AADI.US) Officer Sells US$90,614.17 in Common Stock
$Aadi Biosciences(AADI.US)$ Officer Desai Neil sold 40,000 shares of Common Stock on Apr 1, 2, 2024 at an average price of $2.2654 for a total value of $90,614.17.Source: Announcement What is statemen
moomoo NewsApr 3 17:33 ET
Express News | Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With Nab-Sirolimus At Society Of Gynecologic Oncology
Moomoo 24/7Mar 18 02:24 ET
Aadi Bioscience Presents New Subgroup Analysis of Patients With Advanced Malignant PEComa of Gynecologic Origin Treated With Nab-Sirolimus at Society of Gynecologic Oncology (SGO)
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers...
PR NewswireMar 17 08:00 ET
Express News | Aadi Bioscience Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results
Moomoo 24/7Mar 13 15:33 ET
Earnings Call Summary | Aadi Biosciences(AADI.US) Q4 2023 Earnings Conference
The following is a summary of the Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript:Financial Performance:Aadi Bioscience reported impressive sales growth with full-year sales for FYARRO h
moomoo AIMar 13 12:13 ET · Conference Call
Aadi Bioscience Cash Runway Extends to 4Q 2025 >AADI
Aadi Bioscience Cash Runway Extends to 4Q 2025 >AADI
Dow JonesMar 13 08:04 ET
Express News | Aadi Bioscience's Cash, Cash Equivalents And Short-term Investments As Of December 31, 2023, Is Expected To Fund Operations Into Q4 2025 Based On Current Plans
Moomoo 24/7Mar 13 08:03 ET
Aadi Bioscience 4Q Loss/Shr 60c >AADI
Aadi Bioscience 4Q Loss/Shr 60c >AADI
Dow JonesMar 13 08:03 ET
Aadi Bioscience GAAP EPS of -$0.60 Beats by $0.05, Revenue of $6.33M Beats by $0.03M
Seeking AlphaMar 13 08:02 ET
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M
08:01 AM EDT, 03/13/2024 (MT Newswires) -- Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M
MT NewswiresMar 13 08:01 ET
Press Release: Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
LOS ANGELES, March 13, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and highlighted recent corporate progress.
Dow JonesMar 13 08:00 ET
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. • Silence Therapeutics (NASDAQ:SLN) is expec
BenzingaMar 13 06:15 ET
Aadi Bioscience Q4 2023 Earnings Preview
Seeking AlphaMar 12 10:50 ET
Aadi Bioscience, Inc.'s (NASDAQ:AADI) Shares Bounce 27% But Its Business Still Trails The Industry
Those holding Aadi Bioscience, Inc. (NASDAQ:AADI) shares would be relieved that the share price has rebounded 27% in the last thirty days, but it needs to keep going to repair the recent damage it has
Simply Wall StMar 8 06:54 ET
Aadi Biosciences(AADI.US) Officer Sells US$84,641.19 in Common Stocks
$Aadi Biosciences(AADI.US)$ Officer Desai Neil sold 42,000 shares of Common Stocks on Mar 1, 4, 2024 at an average price of $2.0153 for a total value of $84,641.19.Source: Announcement What is stateme
moomoo NewsMar 4 20:04 ET
Stocks to Watch: BioVie, Aadi Bioscience
By Sabela Ojea BioVie on Friday said it's planning a public offering of common stock and warrants. Shares of the biotechnology company dropped 21% to $1.50 in after-hours trading. Aadi Bioscience sa
WSJMar 1 18:45 ET
Trending Stocks Today: Ainos Surges 56.19% Post-Market
March 1st - US stocks trending post-market.Gainers: $Ainos(AIMD.US)$ soars 56.19% to $1.64 with a turnover of $5.12 million. $Aadi Biosciences(AADI.US)$ shoots up 28.64% to $2.47 with a turnover of $5
moomoo NewsMar 1 17:45 ET
Aadi Bioscience Reports Supportive Data From Tumor Treatment Trial -- Shares Jump After Hours
Aadi Bioscience (AADI) said late Friday that data from a long-term efficacy and safety trial further supports Fyarro to treat malignant perivascular epithelioid cell tumor, or PEComa. The results from
MT NewswiresMar 1 16:51 ET
12 Health Care Stocks Moving In Friday's After-Market Session
GainersAinos (NASDAQ:AIMD) stock moved upwards by 54.3% to $1.62 during Friday's after-market session. The company's market cap stands at $7.5 million. Aadi Bioscience (NASDAQ:AADI) shares rose 38.54%
BenzingaMar 1 16:32 ET
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with...
PR NewswireMar 1 16:08 ET
No Data
No Data